Neurophet, a Korean company specializing in artificial intelligence (AI) solutions for brain imaging analysis, said that it will participate in the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2025), taking place from Tuesday to Saturday this week in Vienna, Austria.

At the conference, Neurophet will unveil its Alzheimer’s-focused brain imaging software, Neurophet AQUA AD, which provides quantitative analysis of MRI and PET scans to support prescription decisions, monitor treatment efficacy, and track side effects of Alzheimer’s antibody therapies.

The solution enables precise analysis throughout the entire course of treatment with anti-Alzheimer’s drugs, such as Eisai and Biogen’s Leqembi (ingredient: lecanemab) and Eli Lilly’s Kisunla (ingredient: donanemab), which require close monitoring due to their potential side effects.

As pharmaceutical companies ramp up their clinical research on Alzheimer’s treatments, interest in quantitative brain imaging biomarkers is also growing, further drawing global attention to Neurophet AQUA AD.

Neurophet will also introduce its core products Neurophet AQUA and Neurophet SCALE PET, at its exhibition booth. Neurophet AQUA is designed to analyze brain MRI data to assess atrophy and white matter changes typically observed in neurodegenerative diseases such as Alzheimer’s and vascular dementia. Neurophet SCALE PET combines PET and MRI imaging to provide quantitative analysis of biomarkers labeled with radiotracers.

Through its participation in AD/PD 2025, Neurophet aims to expand strategic partnerships with major global pharmaceutical companies and potential clients, while showcasing the technical strengths and competitiveness of its core product lineup. The company also plans to hold in-depth meetings with leading neurologists and key opinion leaders (KOLs) from various countries.

“As global clinical trials for Alzheimer’s treatments continue to accelerate, Neurophet AQUA AD is receiving increased attention as a key tool for biomarker development based on brain imaging,” Neurophet Co-CEO Been Jun-kil said. “We will strengthen our strategic partnerships with global pharmaceutical companies and neurological KOLs through this year’s AD/PD conference.”